logo

Verona Pharma Plc (VRNA)



Trade VRNA now with
  Date
  Headline
2/14/2020 2:33:21 AM Verona Announces Publication Of Phase 2b Trial Results For Ensifentrine
1/13/2020 12:16:27 AM Verona Pharma Reports Positive Results From Phase IIb Trial Of Nebulized Ensifentrine As An Add-on To Inhaled Tiotropium
1/7/2020 2:17:49 AM Verona Pharma Appoints David Moskowitz As VP, Capital Markets Strategy & Investor Relations
10/17/2019 2:39:15 AM Verona Completes Enrollment In Phase 2b Clinical Trial With Nebulized Ensifentrine In Moderate-to-severe COPD
10/17/2019 2:06:35 AM Verona Completes Enrollment In Phase 2b Clinical Trial With Nebulized Ensifentrine
8/5/2019 2:08:18 AM Verona Announces Positive Phase 2 Data With DPI Formulation Of Ensifentrine
7/29/2019 7:19:42 AM Wedbush Reiterates Verona Pharma plc (VRNA) At Outperform With $58 Price Target
5/13/2019 6:59:05 AM Wedbush Is Lowering Verona Pharma plc (VRNA) FY20 Estimate To -0.42 From -0.19
5/13/2019 6:58:52 AM Wedbush Is Cutting Verona Pharma plc (VRNA) Q4 20 Estimate To -0.14 From -0.09
5/13/2019 6:58:39 AM Wedbush Is Lowering Verona Pharma plc (VRNA) Q3 20 Estimate To -0.09 From 0.03
5/13/2019 6:58:14 AM Wedbush Is Lowering Verona Pharma plc (VRNA) Q2 20 Estimate To -0.10 From -0.06
5/13/2019 6:57:47 AM Wedbush Is Lowering Verona Pharma plc (VRNA) FY19 Estimate To -0.31 From -0.18
5/13/2019 6:57:28 AM Wedbush Is Cutting Verona Pharma plc (VRNA) Q4 19 Estimate To -0.08 From -0.05
5/13/2019 6:57:21 AM Wedbush Is Lowering Verona Pharma plc (VRNA) Q3 19 Estimate To -0.08 From -0.05
5/13/2019 6:57:10 AM Wedbush Is Lowering Verona Pharma plc (VRNA) Q2 19 Estimate To -0.08 From -0.05
5/13/2019 6:56:27 AM Wedbush Reiterates Verona Pharma plc (VRNA) At Outperform With $58 Up From $56 Price Target
4/9/2019 2:34:01 AM Verona Pharma Granted Key EU Patent Related To Late-stage COPD Clinical Candidate Ensifentrine